Evidence map›Paper›PMID 39779507›Full record

ArticlePediatric nephrology (Berlin, Germany)2025

The beneficial effect of adding belimumab in severe and refractory IgA nephropathy: a case report.

Youying Mao, Chenxing Zhang, Jing Xu, Chong Liu, Song Guo Zheng, Lei Yin

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Youying Mao *Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0002-7598-7386
Chenxing Zhang *Department of Nephrology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Jing XuDepartment of Nephrology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Chong LiuDepartment of Pediatrics, Songjiang Hospital Affiliated to the Shanghai Jiaotong University School of Medicine, Shanghai, China.
Song Guo ZhengDepartment of Immunology, School of Cell and Gene Therapy, Songjiang Research Institute, Songjiang Hospital Affiliated to the Shanghai Jiaotong University School of Medicine, Shanghai, China. Zheng@shsmu.edu.cn.
Lei YinDepartment of Nephrology, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China. scmckidney2022@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and is the most common cause of chronic kidney disease (CKD) in China. It lacks recommended treatment in refractory IgAN after conventional therapy. Belimumab, a recombinant human IgG-1λ monoclonal antibody that inhibits the B lymphocyte stimulator, is recommended to treat active lupus nephritis. This report presents a case of a child with severe and refractory IgAN who showed kidney response after belimumab addition combined with conventional therapy. The therapy result was accompanied by decreased plasma cells in peripheral blood. It is the first case showing the benefits of adding belimumab to other immunosuppressive regimens.

Indexed as

Antibodies, Monoclonal, HumanizedGlomerulonephritis, IGAImmunosuppressive AgentsAdolescentDrug Therapy, CombinationFemaleHumansSeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, HumanizedbelimumabImmunosuppressive AgentsBelimumabCase reportIgA nephropathy

Identifiers

PMID39779507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.